Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.

@article{Nicholson2005GrowthFS,
  title={Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.},
  author={Robert Ian Nicholson and Iain R. Hutcheson and Stephen E. Hiscox and Janice M. Knowlden and Merete Giles and Denise Barrow and Julia M. W. Gee},
  journal={Endocrine-related cancer},
  year={2005},
  volume={12 Suppl 1},
  pages={S29-36}
}
De novo insensitivity and acquired resistance to the selective oestrogen receptor modulator tamoxifen and the pure anti-oestrogen fulvestrant (faslodex) severely limit their effectiveness in breast cancer patients. This is a major clinical problem, since each year upward of 1 million women are dispensed anti-oestrogenic drugs. In order to investigate the phenomenon of anti-oestrogen resistance and to rapidly screen drugs that target the resistance mechanism(s), we have previously established… CONTINUE READING